Sales & Marketing News | pharmaphorum

News

Enhertu gets first okay for HER2-ultralow breast cancer

Enhertu gets much-anticipated new FDA approval in breast cancer that expands its label and makes it an earlier option in the treatment pathway.

News

Sage rejects Biogen takeover and launches review

Sage Therapeutics has unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company.

News

Italian decision sets up launch of Oncopeptides' Pepaxti

Oncopeptides hopes to reignite growth in multiple myeloma drug Pepaxti after getting reimbursement approval in Italy.

News

Pfizer offers $60m to settle prescriber kickback claims

Pfizer has paid $60m to settle US government allegations that its Biohaven unit made improper payments to prescribers of its migraine drug Nurtec ODT.

News

UnitedHealth names CEO to replace slain Thompson

UnitedHealth has appointed company veteran Tim Noel as CEO of its UnitedHealthcare insurance unit, after the murder last month of Brian Thompson.

News

Purdue and Sacklers agree new $7.4bn opioid settlement

Purdue Pharma and the Sackler family who own the company have proposed a new $7.4 billion settlement to resolve thousands of opioid-related lawsuits.

Enhertu gets first okay for HER2-ultralow breast cancer

Sage rejects Biogen takeover and launches review

Italian decision sets up launch of Oncopeptides' Pepaxti

Pfizer offers $60m to settle prescriber kickback claims

UnitedHealth names CEO to replace slain Thompson

Purdue and Sacklers agree new $7.4bn opioid settlement

US pharma tariffs of up to 100% finalised by Trump

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks